Dementia and Geriatric Cognitive Disorders

Ota M.a· Nemoto K.a· Nemoto M.b· Numata Y.b· Kitabatake A.b· Yamada Y.c· Shinkawa K.c· Kobayashi M.c· Arai T.a

Author affiliations

aDivision of Clinical Medicine, Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
bUniversity of Tsukuba Hospital, Tsukuba, Japan
cIBM Research, Tokyo, Japan

Dement Geriatr Cogn Disord

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: July 20, 2022
Accepted: October 03, 2022
Published online: December 27, 2022

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

Introduction: Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) have long prodromal phases without dementia. However, the patterns of cerebral network alteration in this early stage of the disease remain to be clarified. Method: Participants were 48 patients with mild cognitive impairment (MCI) due to AD (MCI-AD), 18 patients with MCI with DLB (MCI with Lewy bodies: MCI-LB), and 23 healthy controls who underwent a 1.5-Tesla magnetic resonance imaging scan. Cerebral networks were extracted from individual T1-weighted images based on the intracortical similarity, and we estimated the differences of network metrics among the three diagnostic groups. Results: Whole-brain analyses for degree, betweenness centrality, and clustering coefficient images were performed using SPM8 software. The patients with MCI-LB showed significant reduction of degree in right putamen, compared with healthy subjects. The MCI-AD patients showed significant lower degree in left insula and bilateral posterior cingulate cortices compared with healthy subjects. There were no significant differences in small-world properties and in regional gray matter volume among the three groups. Conclusions: We found the change of degree in the patients with MCI-AD and with MCI-LB, compared with healthy controls. These findings were consistent with the past single-photon emission computed tomography studies focusing on AD and DLB. The disease-related difference in the cerebral neural network might provide an adjunct biomarker for the early detection of AD and DLB.

© 2022 S. Karger AG, Basel

References Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214–28. Ferman TJ, Smith GE, Kantarci K, Boeve BF, Pankratz VS, Dickson DW, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013;81(23):2032–8. McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743–55. Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry. 2011;12(1):2–32. Sato H, Nakaaki S, Sato J, Shikimoto R, Furukawa TA, Mimura M, et al. Caregiver self-efficacy and associated factors among caregivers of patients with dementia with Lewy bodies and caregivers of patients with Alzheimer’s disease. Psychogeriatrics. 2021;21(5):783–94. Blanc F, Colloby SJ, Cretin B, de Sousa PL, Demuynck C, O’Brien JT, et al. Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther. 2016;8:31. Roquet D, Noblet V, Anthony P, Philippi N, Demuynck C, Cretin B, et al. Insular atrophy at the prodromal stage of dementia with Lewy bodies: a VBM DARTEL study. Sci Rep. 2017;7(1):9437. Firbank MJ, Durcan R, O’Brien JT, Allan LM, Barker S, Ciafone J, et al. Hippocampal and insula volume in mild cognitive impairment with Lewy bodies. Parkinsonism Relat Disord. 2021;86:27–33. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10(3):186–98. Lazarou I, Nikolopoulos S, Dimitriadis SI, Yiannis Kompatsiaris I, Spilioti M, Tsolaki M. Is brain connectome research the future frontier for subjective cognitive decline? A systematic review. Clin Neurophysiol. 2019;130(10):1762–80. Chabran E, Noblet V, Loureiro de Sousa P, Demuynck C, Philippi N, Mutter C, et al. Changes in gray matter volume and functional connectivity in dementia with Lewy bodies compared to Alzheimer’s disease and normal aging: implications for fluctuations. Alzheimers Res Ther. 2020;12(1):9. Peraza LR, Taylor JP, Kaiser M. Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging. 2015;36(9):2458–67. Schumacher J, Peraza LR, Firbank M, Thomas AJ, Kaiser M, Gallagher P, et al. Functional connectivity in dementia with Lewy bodies: a within- and between-network analysis. Hum Brain Mapp. 2018;39(3):1118–29. Tijms BM, Seriès P, Willshaw DJ, Lawrie SM. Similarity-based extraction of individual networks from gray matter MRI scans. Cereb Cortex. 2012;22(7):1530–41. Dicks E, van der Flier WM, Scheltens P, Barkhof F, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer’s disease. Neurobiol Aging. 2020;94:71–80. Tijms BM, Moller C, Vrenken H, Wink AM, de Haan W, van der Flier WM, et al. Single-Subject grey matter graphs in Alzheimer’s disease. PLoS One. 2013;8(3):e58921. Dicks E, Tijms BM, Ten Kate M, Gouw AA, Benedictus MR, Teunissen CE, et al. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol Aging. 2018;61:198–206. Tijms BM, Ten Kate M, Gouw AA, Borta A, Verfaillie S, Teunissen CE, et al. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease. Neurobiol Aging. 2018;61:75–81. Pelkmans W, Vromen EM, Dicks E, Scheltens P, Teunissen CE, Barkhof F, et al. Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline. Brain Commun. 2022;4(2):fcac026. Tijms BM, Sprooten E, Job D, Johnstone EC, Owens DGC, Willshaw D, et al. Grey matter networks in people at increased familial risk for schizophrenia. Schizophr Res. 2015;168(1–2):1–8. van Duinkerken E, Ijzerman RG, Klein M, Moll AC, Snoek FJ, Scheltens P, et al. Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Hum Brain Mapp. 2016;37(3):1194–208. Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, et al. Gray matter networks and cognitive impairment in multiple sclerosis. Mult Scler. 2019;25(3):382–91. Ideno Y, Takayama M, Hayashi K, Takagi H, Sugai Y. Evaluation of a Japanese version of the mini mental state examination in elderly persons. Geriatr Gerontol Int. 2012;12(2):310–6. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4. Wechsler D. Wechsler memory scale-revised. San Antonio: Psychological Corporation; 1987. American Psychiatric Association. DSM-V: diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C: American Psychiatric Press; 2013. Edmonds EC, McDonald CR, Marshall A, Thomas KR, Eppig J, Weigand AJ, et al. Early versus late MCI: improved MCI staging using a neuropsychological approach. Alzheimers Dement. 2019;15(5):699–708. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447–55. Ota M, Numata Y, Kitabatake A, Tsukada E, Kaneta T, Asada T, et al. Structural brain network correlations with amyloid burden in elderly individuals at risk of Alzheimer’s disease. Psychiatry Res Neuroimaging. 2022;319:111415. Ota M, Nemoto K, Ishida I, Sato S, Asada T, Arai T, et al. Structural brain network correlated with the resilience to traumatic events in the healthy participants: an MRI study on healthy people in a stricken area of the Great East Japan Earthquake. Psychol Trauma. 2022;14(6):1035–9. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O’Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: an MRI study. Neurology. 2003;61(9):1191–5. Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease. J Nucl Med. 2007;48(5):704–11. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. Firbank MJ, O’Brien JT, Durcan R, Allan LM, Barker S, Ciafone J, et al. Mild cognitive impairment with Lewy bodies: blood perfusion with arterial spin labelling. J Neurol. 2021;268(4):1284–94. Middelkoop HA, van der Flier WM, Burton EJ, Lloyd AJ, Paling S, Barber R, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology. 2001;57(11):2117–20. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain. 2007;130(Pt 3):708–19. Yang J, Pan P, Song W, Huang R, Li J, Chen K, et al. Voxelwise meta-analysis of gray matter anomalies in Alzheimer’s disease and mild cognitive impairment using anatomic likelihood estimation. J Neurol Sci. 2012;316(1–2):21–9. López-Sanz D, Garcés P, Álvarez B, Delgado-Losada ML, López-Higes R, Maestú F. Network disruption in the preclinical stages of Alzheimer’s disease: from subjective cognitive decline to mild cognitive impairment Available from. Int J Neural Syst. 2017;27(8):1750041. Lazarou I, Georgiadis K, Nikolopoulos S, Oikonomou VP, Tsolaki A, Kompatsiaris I, et al. A novel connectome-based electrophysiological study of subjective cognitive decline related to Alzheimer’s disease by using resting-state high-density EEG EGI GES 300. Brain Sci. 2020;10(6):392. Wang XN, Zeng Y, Chen GQ, Zhang YH, Li XY, Hao XY, et al. Abnormal organization of white matter networks in patients with subjective cognitive decline and mild cognitive impairment. Oncotarget. 2016;7(31):48953–62. Pereira JB, Mijalkov M, Kakaei E, Mecocci P, Vellas B, Tsolaki M, et al. Disrupted network topology in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease. Cereb Cortex. 2016;26(8):3476–93. Yao Z, Zhang Y, Lin L, Zhou Y, Xu C, Jiang T, et al. Abnormal cortical networks in mild cognitive impairment and Alzheimer’s disease. PLoS Comput Biol. 2010;6(11):e1001006. Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, et al. Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129(5):729–48. Ferman TJ, Aoki N, Crook JE, Murray ME, Graff-Radford NR, van Gerpen JA, et al. The limbic and neocortical contribution of alpha-synuclein, tau, and amyloid beta to disease duration in dementia with Lewy bodies. Alzheimers Dement. 2018;14(3):330–9. Thomas AJ, Donaghy P, Roberts G, Colloby SJ, Barnett NA, Petrides G, et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol Med. 2019;49(3):396–402. Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One. 2015;10(3):e0120540. Article / Publication Details

First-Page Preview

Received: July 20, 2022
Accepted: October 03, 2022
Published online: December 27, 2022

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.